logo
Pretending We Don't Owe Money Doesn't Mean We Don't Owe Money

Pretending We Don't Owe Money Doesn't Mean We Don't Owe Money

Forbesa day ago
DORCHESTER - APRIL 05: Dominique Entzminger, a physician assistant of family medicine, wears a ... More stethoscope during an examination at the Codman Square Health Center April 5, 2006 in Dorchester, Massachusetts. State lawmakers approved a health care reform bill March 4 that would make Massachusetts the first state in the nation to require all its citizens have some form of health insurance. Governor Mitt Romney is scheduled to sign the bill next week. (Photo by)
Markets always have their say. This was recently acknowledged, at least implicitly, by a federal judge in Texas. Judge Sean Jordan ruled against a Biden-era decree from the Consumer Financial Protection Bureau that tens of billions worth of medical debt be excluded from credit reports.
Jordan should be cheered for his ruling. But not just because it signals rationality on his part. Jordan most rates credit for protecting the health of consumers. Think about it.
As evidenced by the $49 billion worth of medical debt that the CFPB wanted removed from the credit reports of 15 million people, there's a very real need for medical-related care in the United States. Put another way, no one runs up medical debt just because.
Which speaks to the foolhardy nature of the initial CFPB decree. Imagine if it had held such that debt related to healthcare could be left off credit reports. If so, it would on its face increase the incentive among those with medical debt to cease paying it, all based on the presumption that a failure to keep current on debts wouldn't shrink one's credit score.
It might seem harmless to some at first glance, but for the problem that unpaid bills don't just happen. There's a market reaction to a failure to pay. Specifically, a rising tendency for medical debts to go unpaid would most certainly result in reduced availability of medical care for all would-be patients.
What else would doctors and medical professionals be expected to do? If going forward the pretense will be that medical debt doesn't exist on the matter of credit reports, logic dictates that medical care on credit would have to shrink to reflect the decree.
Which is just a comment that when governments err to protect a few, or even millions, the burden is suffered by exponentially more. If there's no punishment in a credit sense for ignoring certain bills, then it only makes sense that would-be patients will similarly be ignored to the extent that their capacity to pay isn't trusted as much thanks to a few, or many, bad apples. And it won't just be limited to medical care. See yet again how much in the way of debt that the CFPB wanted erased from credit reports.
Stated simply, $49 billion isn't exactly a tiny number. Which means that if it can no longer reflect on credit reports, the worth of credit reports themselves will decline. It's the housing equivalent of a home appraisal, albeit one that lacks crucial information like square footage, bedroom and bathroom count, along with whether the house has central air conditioning. Would you buy such a house sight unseen? Hopefully the question answers itself.
Ideally it also explains the importance of credit reports reflecting reality, as opposed to a truncated version of the latter. Absent the truth, how can any provider of goods and services (not just a doctor or a hospital) confidently provide them on a to-be-paid basis? Which is a reminder of the point made at the beginning of this piece, that markets always have their say.
It's worth remembering as states contemplate doing locally what Judge Jordan stood athwart nationally. That which obscures reality doesn't alter reality, which means statewide decrees meant to mirror the CFPB's attempted one will not just harm consumer health, but their ability to attain goods and services more broadly.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Jim Cramer Says He 'Was Discouraged to Get a Mixed Update from Abbott Labs'
Jim Cramer Says He 'Was Discouraged to Get a Mixed Update from Abbott Labs'

Yahoo

time12 minutes ago

  • Yahoo

Jim Cramer Says He 'Was Discouraged to Get a Mixed Update from Abbott Labs'

Abbott Laboratories (NYSE:ABT) is one of the stocks that Jim Cramer shed light on. Commenting on the company's recent earnings report results, Cramer said: 'Today, in an otherwise positive market, I was discouraged to get a mixed update from Abbott Labs, medical technology company that we've long owned for the Charitable Trust… I'd say two decades. When Abbott Labs reported this morning, the… results were perfectly solid. Management tightened their full-year earnings guidance rather than raising it while also taking down their organic sales growth forecast and their operating margin outlook. wavebreakmedia/ Abbott (NYSE:ABT) is a healthcare company engaged in the research, development, manufacture, and marketing of a wide range of medical products. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition
Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition

Yahoo

time12 minutes ago

  • Yahoo

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition

Eli Lilly and Company (NYSE:LLY) is one of the . Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company (NYSE:LLY) is a research-driven pharmaceutical leader headquartered in Indiana. With a 150-year history, the company carries on the business of discovering, developing, manufacturing, and marketing innovative treatments across diseases like diabetes and in fields like oncology, immunology, and neuroscience. Some of the company's notable products, such as Humalog, Trulicity, Mounjaro, and Zepbound, are marketed in over 125 countries. The company is carrying on multiple studies and its latest updates include the Phase 2b clinical study titled 'A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa' and Phase 3 clinical study titled 'A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ LY3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on a Background Therapy With Intranasal Corticosteroids.' Along with these studies, the company has a pipeline with potential drugs capable of generating more than $1 billion in annual revenue. Amid these studies, the company has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion. With this acquisition, Eli Lilly and Company (NYSE:LLY) aims to strengthen its positions in gene editing for cardiovascular conditions. With a beta of 0.44 signaling the company's resistance to market conditions, Eli Lilly and Company (NYSE:LLY) has a high anticipated 5-year EPS growth of 41.87%, making the stock a strong contender in our list. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None.

Vektor Medical's vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care
Vektor Medical's vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care

Yahoo

time12 minutes ago

  • Yahoo

Vektor Medical's vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care

Milestone Highlights Rapid Hospital Adoption and Clinical Demand for Arrhythmia Insights that Improve Outcomes and Reduce Procedure Time SAN DIEGO, July 23, 2025--(BUSINESS WIRE)--Vektor Medical today announced its vMap® system has been used in more than 2,000 procedures in the U.S., a milestone that underscores its rapid adoption by electrophysiologists (EPs) and hospitals seeking to improve procedural efficiency, reduce repeat interventions, and deliver better patient outcomes. vMap, developed with AI and designed to localize both focal and fibrillation-type arrhythmias, delivers actionable insights in all four chambers of the heart in less than a minute. Clinical studies have shown that use of vMap is associated with a reduction in procedure time, which may reduce fluoroscopy time and improve safety. vMap integrates seamlessly into existing systems, making it an increasingly valuable solution for electrophysiologists seeking greater efficiency and performance without compromise. vMap is now in use at over 20 hospitals throughout the United States. "vMap has become an integral part of how I care for patients," said Dr. Anish Amin, Section Chief, Electrophysiology, OhioHealth Heart and Vascular. "It's efficient, non-invasive, and delivers insights that enhance every stage of the ablation process from planning through execution. With vMap, I can pinpoint arrhythmia sources faster with greater confidence, treat more accurately, and potentially reduce repeat interventions for patients. I'm looking forward to enrolling patients in the IMPRoVED-AF study, which will further validate the clinical impact of this technology and its potential to transform how we approach AF ablation." As adoption of pulsed field ablation (PFA) accelerates, the need for accurate, accessible data is greater than ever. vMap can enhance the impact of PFA by helping EPs identify optimal ablation targets before entering the lab and reiteratively during the procedure. With vMap's rapid, non-invasive ECG-based driver localization, physicians have more information to better target areas of interest, supporting more efficient procedures and unlocking the full potential of PFA. "This milestone represents meaningful momentum," said Robert Krummen, CEO of Vektor Medical. "With every procedure, physicians are leveraging vMap's rapid, non-invasive insights to make informed decisions and streamline care. We're seeing growing demand quarter over quarter as both physicians and hospitals look for ways to enhance efficiency and elevate patient care." The vMap system is FDA-cleared and commercially available in the United States. As clinical use continues to expand, Vektor Medical remains focused on advancing the future of arrhythmia care through clinical innovation, strategic partnerships, and physician impact. To learn more about Vektor Medical, vMap technology, or to request a clinical or strategic briefing, visit and connect with us on LinkedIn and X. About Vektor Medical Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia drivers more quickly and with greater accuracy, Vektor is improving outcomes, enhancing efficiencies, and accelerating access to effective treatment strategies. To learn more, visit View source version on Contacts Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store